{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:12:13Z","timestamp":1748578333778,"version":"3.41.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jfma.2024.08.020","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T19:26:18Z","timestamp":1723922778000},"page":"502-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unmet needs in the clinical management of chronic hepatitis B infection"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-6881","authenticated-orcid":false,"given":"Peter D.","family":"Block","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-8128","authenticated-orcid":false,"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2024.08.020_bib1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jama.1965.03080070025007","article-title":"A \u201cnew\u201d antigen in leukemia sera","volume":"191","author":"Blumberg","year":"1965","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0168-8278(03)00157-0","article-title":"The unexpected outcomes of medical research: serendipity and the Australia antigen","volume":"39","author":"Alter","year":"2003","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2018.10.048","article-title":"What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats","volume":"156","author":"Ward","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jfma.2024.08.020_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep4.1476","article-title":"How durable is functional cure (hepatitis B surface antigen loss) in patients with chronic hepatitis B treated with current antivirals?","volume":"4","author":"Loglio","year":"2020","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/oxfordjournals.aje.a112370","article-title":"THE e antigen and vertical transmission of hepatitis B surface antigen","volume":"105","author":"Beasley","year":"1977","journal-title":"Am J Epidemiol"},{"issue":"12","key":"10.1016\/j.jfma.2024.08.020_bib8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: a modelling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jfma.2024.08.020_bib9","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"issue":"1, Part 1","key":"10.1016\/j.jfma.2024.08.020_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jfma.2018.11.008","article-title":"Taiwan consensus statement on the management of chronic hepatitis B","volume":"118","author":"Chien","year":"2019","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2013.02.015","article-title":"Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention","volume":"59","author":"Wen","year":"2013","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jfma.2024.08.020_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2893.2010.01333.x","article-title":"Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants","volume":"18","author":"Singh","year":"2011","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.24500","article-title":"Fighting against viral hepatitis: lessons from Taiwan","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatol Baltim Md"},{"issue":"7","key":"10.1016\/j.jfma.2024.08.020_bib16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jiy706","article-title":"The impact of universal infant hepatitis B immunization on reducing the hepatitis B carrier rate in pregnant women","volume":"220","author":"Su","year":"2019","journal-title":"J Infect Dis"},{"issue":"Suppl 9","key":"10.1016\/j.jfma.2024.08.020_bib17","doi-asserted-by":"crossref","first-page":"J36","DOI":"10.1016\/j.vaccine.2012.11.061","article-title":"Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation","volume":"31","author":"Cui","year":"2013","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.jfma.2024.08.020_bib18","article-title":"Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus","volume":"5","author":"Matthews","year":"2023","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.jfma.2024.08.020_bib19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.gastro.2011.12.035","article-title":"Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV","volume":"142","author":"Chen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2024.08.020_bib20","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/s41467-021-26475-6","article-title":"The impact of the timely birth dose vaccine on the global elimination of hepatitis B","volume":"12","author":"de Villiers","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jfma.2024.08.020_bib21","doi-asserted-by":"crossref","first-page":"e3317","DOI":"10.1093\/cid\/ciaa898","article-title":"Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus","volume":"73","author":"Huang","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"issue":"10","key":"10.1016\/j.jfma.2024.08.020_bib22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.11622\/smedj.2015194","article-title":"Limited benefit of hepatitis B immunoglobulin prophylaxis in children of hepatitis B e antigen-negative mothers","volume":"57","author":"Lee","year":"2016","journal-title":"Singapore Med J"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/jac\/dku404","article-title":"Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+\/HBeAg\u2212 mothers: a systematic review and meta-analysis","volume":"70","author":"Machaira","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.jfma.2024.08.020_bib24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1473-3099(22)00206-7","article-title":"Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial","volume":"22","author":"Segeral","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12072-020-10026-0","article-title":"Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis","volume":"14","author":"Wu","year":"2020","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.jfma.2024.08.020_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251552","article-title":"Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV","volume":"16","author":"Pan","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.jfma.2024.08.020_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2024.08.020_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.jfma.2024.08.020_bib33","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.3748\/wjg.v27.i33.5536","article-title":"Surveillance for hepatocellular carcinoma in chronic viral hepatitis: is it time to personalize it?","volume":"27","author":"Demirtas","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jfma.2024.08.020_bib34","first-page":"461","article-title":"Incorporating serum level of hepatitis B surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis","volume":"14","author":"Yang","year":"2016","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.gastro.2014.02.033","article-title":"Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine","volume":"147","author":"Lim","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jfma.2024.08.020_bib36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.gastro.2013.02.002","article-title":"Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment","volume":"144","author":"Wong","year":"2013","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jfma.2024.08.020_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.08.020_bib38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10620-017-4448-7","article-title":"Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients: validation of the page-B score to predict hepatocellular carcinoma","volume":"62","author":"Riveiro-Barciela","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.jfma.2024.08.020_bib39","first-page":"1788","article-title":"Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir","volume":"37","author":"Kim","year":"2017","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"5","key":"10.1016\/j.jfma.2024.08.020_bib40","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jfma.2024.08.020_bib41","first-page":"1624","article-title":"External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy","volume":"39","author":"Lee","year":"2019","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"8","key":"10.1016\/j.jfma.2024.08.020_bib42","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/ajg.2014.157","article-title":"Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy","volume":"109","author":"Lee","year":"2014","journal-title":"Off J Am Coll Gastroenterol ACG"},{"doi-asserted-by":"crossref","unstructured":"Jung KS, Kim SU, Song K, et al. Validation of hepatitis B virus\u2013related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology. 62(6):1757. doi:10.1002\/hep.28115.","key":"10.1016\/j.jfma.2024.08.020_bib43","DOI":"10.1002\/hep.28115"},{"issue":"68","key":"10.1016\/j.jfma.2024.08.020_bib44","doi-asserted-by":"crossref","first-page":"113213","DOI":"10.18632\/oncotarget.22375","article-title":"Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study","volume":"8","author":"Seo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jfma.2024.08.020_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2023.05.029","article-title":"Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy","author":"Kim","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jhep.2021.09.025","article-title":"An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B","volume":"76","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"issue":"0","key":"10.1016\/j.jfma.2024.08.020_bib47","article-title":"A liver stiffness-based etiology-independent machine learning algorithm to predict hepatocellular carcinoma","volume":"0","author":"Lin","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jfma.2024.08.020_bib48","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatol Baltim Md"},{"issue":"9865","key":"10.1016\/j.jfma.2024.08.020_bib49","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatol Baltim Md"},{"issue":"3","key":"10.1016\/j.jfma.2024.08.020_bib51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference\u2021","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2024.08.020_bib52","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jfma.2024.08.020_bib53","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"issue":"S1","key":"10.1016\/j.jfma.2024.08.020_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13291","article-title":"Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)","volume":"37","author":"Grossi","year":"2017","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jfma.2024.08.020_bib55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jfma.2024.08.020_bib56","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"H\u00f6ner zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jfma.2024.08.020_bib57","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen\u2013negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jfma.2024.08.020_bib58","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"B\u00f6mmel","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.08.020_bib59","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jfma.2024.08.020_bib60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.jfma.2024.08.020_bib61","first-page":"1629","article-title":"Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis","volume":"71","author":"Hall","year":"2022","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.jfma.2024.08.020_bib62","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of hepatic decompensation after nucleos(t)ide analog withdrawal: results from a large, international, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jfma.2024.08.020_bib63","article-title":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2022","journal-title":"JHEP Rep"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624003887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624003887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T02:16:26Z","timestamp":1748571386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624003887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0929664624003887"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.08.020","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs in the clinical management of chronic hepatitis B infection","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}